PCRX

PCRX

USD

Pacira BioSciences Inc. Common Stock

$24.450+0.100 (0.411%)

Real-time Price

Healthcare
Drug Manufacturers - Specialty & Generic
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$24.350

High

$24.590

Low

$23.500

Volume

0.18M

Company Fundamentals

Market Cap

1.1B

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

Trading Stats

Avg Volume

0.89M

Exchange

NMS

Currency

USD

52-Week Range

Low $11.16Current $24.450High $29.61

Related News

GlobeNewswire

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

PHILADELPHIA, May 26, 2025 (GLOBE NEWSWIRE) -- DoubleVerify Holdings, Inc. (NYSE:DV): If you have held DoubleVerify Holdings, Inc. (NYSE:DV) shares since prior to November 10, 2023, and would like to learn

View more
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
GlobeNewswire

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at

View more
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee